MORBIDITY AND MORTALITY FOLLOWING LAPAROSCOPIC-ASSISTED RIGHT HEMICOLECTOMY FOR CANCER

Citation
El. Bokey et al., MORBIDITY AND MORTALITY FOLLOWING LAPAROSCOPIC-ASSISTED RIGHT HEMICOLECTOMY FOR CANCER, Diseases of the colon & rectum, 39(10), 1996, pp. 24-28
Citations number
18
Categorie Soggetti
Gastroenterology & Hepatology
ISSN journal
00123706
Volume
39
Issue
10
Year of publication
1996
Supplement
S
Pages
24 - 28
Database
ISI
SICI code
0012-3706(1996)39:10<24:MAMFLR>2.0.ZU;2-P
Abstract
PURPOSE: This study was undertaken to compare morbidity, mortality, an d pathology after laparoscopically assisted right hemicolectomy (LARHC ) or open right hemicolectomy (ORHC) for cancer of the right colon. ME THODS: Patients undergoing either LARHC or ORHC for invasive carcinoma of the right colon during a 30-month period were studied. Data were c ollected from two sources. All morbidity, mortality, and pathology dat a were collected prospectively in a form suitable for computer storage and analysis as part of the ongoing Concord Hospital Colorectal Cance r Registry. Data concerning in hospital course were obtained by caseno te review. RESULTS: Twenty-eight patients underwent LARHC, and 33 had an ORHC during the study period. The two groups were well matched with respect to age, sex, weight, associated comorbidities, and tumor stag e. Mean operating room use time was significantly higher for LARHC (LA RHC = 261 minutes; ORHC = 203 minutes; P < 0.001). Mean hospital stay from date of resection was the same in both groups (LARHC = 12 days; O RHC = 12.2 days). There was no significant difference between procedur es with respect to postoperative complications, return of gastrointest inal function, or narcotic analgesic requirements. There was a signifi cant shorter distal margin of resection in the LARHC group (ORHC = 13. 4 cm; LARHC = 10 cm; P = 0.03.). Total cost was significantly greater for LARHC ($9,064 vs. $7,881 (Australian); P < 0.001). Median follow-u p was 23.4 months for the LARHC group and 23.9 months for the ORHC gro up. To date, there have been no local or port site recurrences. CONCLU SION: Although there is no difference in morbidity and mortality follo wing LARHC or ORHC, there is no apparent benefit for LARHC.